This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Much Upside is Left in Adaptive Biotechnologies (ADPT)? Wall Street Analysts Think 49.94%
by Zacks Equity Research
The consensus price target hints at a 49.9% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.
Can Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Adaptive Biotechnologies (ADPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Geron (GERN) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q3 sales.
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.
Earnings Preview: NGM Biopharmaceuticals (NGM) Q2 Earnings Expected to Decline
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Adaptive Biotechnologies (ADPT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 46.4% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptive Biotechnologies (ADPT)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adaptive Biotechnologies (ADPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over Adaptive Biotechnologies (ADPT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Adaptive Biotechnologies (ADPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan
by Zacks Equity Research
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 6.98% and 4.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?